Targeting survivin using a combination of miR‑494 and survivin shRNA has synergistic effects on the suppression of prostate cancer growth

Zhu,Jin; Sun,Chenwen; Wang,Liping; Xu,Ming; Zang,Yachen; Zhou,Yibin; Liu,Xiaolong; Tao,Wei; Xue,Boxin; Shan,Yuxi; Yang,Dongrong

doi:10.3892/mmr.2015.4739

Targeting survivin using a combination of miR‑494 and survivin shRNA has synergistic effects on the suppression of prostate cancer growth

Authors:
- Jin Zhu
- Chenwen Sun
- Liping Wang
- Ming Xu
- Yachen Zang
- Yibin Zhou
- Xiaolong Liu
- Wei Tao
- Boxin Xue
- Yuxi Shan
- Dongrong Yang
View Affiliations

Affiliations: Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Published online on: December 30, 2015 https://doi.org/10.3892/mmr.2015.4739
Pages: 1602-1610
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Castration‑resistant prostate cancer (CRPC) remains an obstacle in the current treatment provided for prostate cancer (PCa). Survivin, an apoptosis inhibitor, has been found to be involved in the progression of PCa, and is a promising candidate target for CRPC therapy. Micro (mi)RNAs are involved in the progression of PCa through the regulation of multiple genes. One of the objectives of the present study was to investigate the effect of miRNA (miR)‑494 on the expression of survivin, as well as on PCa growth. The present study also aimed to assess whether co‑transfecting miR‑494 with survivin short hairpin (sh)RNA has synergistic effects on suppressing PCa proliferation or the expression of survivin. Gene Expression Omnibus datasets with clinical PCa miRNA expression profiles were utilized to analysis the expression of miR‑494 in Ca, compared with normal prostate samples. PC3 cells, a CRPC cell line, were transfected with either an miR‑494 expression adenovius, a survivin shRNA adenovirus or the two together, to examine their effect on PCa growth and the expression of survivin in vitro and in vivo. miR‑494 was downregulated in PCa tissue samples and in the PC‑3 cell line. miR‑494 targeted survivin at the translational level in PCa. Overexpression of miR‑494 and silencing survivin RNA through the use of survivin shRNA inhibited the expression of survivin and attenuated PC‑3 cell growth in vitro and in vivo. Notably, co‑transfecting miR‑494 with survivin shRNA had synergistic effects on suppressing prostate cancer proliferation via further suppression of the expression of survivin. These results suggested that using multiple methods to inhibit the function of survivin may have improved efficacy for treating PCa.

View Figures

View References

1	Oliver SE, Gunnell D and Donovan JL: Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet. 355:1788–1789. 2000. View Article : Google Scholar : PubMed/NCBI
2	Zhang M, Latham DE, Delaney MA and Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 24:2474–2482. 2005. View Article : Google Scholar : PubMed/NCBI
3	Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 9:4914–4925. 2003.PubMed/NCBI
4	Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM and Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 100:751–757. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
6	Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, et al: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 31:1080–1085. 2000. View Article : Google Scholar : PubMed/NCBI
7	Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol. 21:315–320. 2002.PubMed/NCBI
8	Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
9	Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M and Hallahan DE: Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 64:2840–2845. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R and Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
11	Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S and Shiina H: Expression of the survivin gene in prostate cancer: Correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol. 171:1855–1860. 2004. View Article : Google Scholar : PubMed/NCBI
12	Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, Shipley WU and Chakravarti A: Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 64:293–302. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S and Manome Y: Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 65:10–19. 2005. View Article : Google Scholar : PubMed/NCBI
14	Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
15	Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
16	Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G and Croce CM: MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA. 109:16570–16575. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM and Kim H: MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res. 17:7584–7594. 2011. View Article : Google Scholar : PubMed/NCBI
18	Diakos C, Zhong S, Xiao Y, Zhou M, Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M and Wiencke JK: TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood. 116:4885–4893. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C, Shan S, Westra W, Sidransky D and Califano JA: MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer. 123:2791–2797. 2008. View Article : Google Scholar : PubMed/NCBI
20	Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 68:6162–6170. 2008. View Article : Google Scholar : PubMed/NCBI
21	Cao C, Mu Y, Hallahan DE and Lu B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene. 23:7047–7052. 2004. View Article : Google Scholar : PubMed/NCBI
22	Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 23:7494–7506. 2004. View Article : Google Scholar : PubMed/NCBI
23	Olie RA, Simões-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2805–2809. 2000.PubMed/NCBI
24	Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and Fujii Y: Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
25	Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KM and Orntoft TF: Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 13:4407–4414. 2007. View Article : Google Scholar : PubMed/NCBI
26	Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 23:968–973. 2012. View Article : Google Scholar
27	Wiechno P, Somer BG, Mellado B, Chłosta PL, Cervera Grau JM, Castellano D, Reuter C, Stöckle M, Kamradt J, Pikiel J, et al: A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol. 65:516–520. 2014. View Article : Google Scholar
28	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
29	Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol. 25:1065–1071. 2004.PubMed/NCBI
30	Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM and Horak ID: Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 29:97–112. 2010. View Article : Google Scholar : PubMed/NCBI
31	Wiechno P, Chlosta P, Smok-Kalwat J, Pikilel J, Henry D, Christianson D, Somer B, Mellado B, Duran I and Castellano D: Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). J Clin Oncol. 29(suppl): abstr 4592. 2011.
32	Song J, Cao L and Li Y: RNA interference-mediated inhibition of survivin and VEGF in pancreatic cancer cells in vitro. Mol Med Rep. 7:1651–1655. 2013.PubMed/NCBI
33	Liu Q, Fu H, Xing R, Tie Y, Zhu J, Sun Z and Zheng X: Survivin knockdown combined with apoptin overexpression inhibits cell growth significantly. Cancer Biol Ther. 7:1053–1060. 2008. View Article : Google Scholar : PubMed/NCBI
34	Shao Y, Liu Y, Shao C, Hu J, Li X, Li F, Zhang L, Zhao D, Sun L, Zhao X, et al: Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein. Cancer Gene Ther. 17:844–854. 2010. View Article : Google Scholar : PubMed/NCBI
35	Baron M, Aslam H, Flasza M, Fostier M, Higgs JE, Mazaleyrat SL and Wilkin MB: Multiple levels of Notch signal regulation. Mol Membr Biol. 19:27–38. 2002. View Article : Google Scholar : PubMed/NCBI
36	Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M and Hu CX: Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol. 23:87–94. 2008. View Article : Google Scholar : PubMed/NCBI
37	Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q, Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion and migration of prostate cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI